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Obj@ives. The aim of this study was to define the tenttNlal 
changes in the relationship lwtwn technetiumd9m tehoroxime 
ttwe retention and mywardtt btcad Row in a canine m&I. 
BOCk&.,,lU”d. Teeh*ettum.99m teboroxime is * new “eYtr.1 
tipophitic myocardiat perfusion agent, It is known to be highly 
extracted by the myocardium but to have a rapid ckarance rate. 
,;.L;,.,L. A aide range ofmyocardial btwd Row was induced 
in each oxporiment by regional coronary occlusion and dipyrida. 
mole infusion. hlyoardial retention of technetium-99m laborox. 
ime was determined by in vitro tissue cowtin9 at 1, 2 or 5 mtn 
after injection of the tracer. Tracer retention was correlated with 
microsphere-determined btoal flow and the data were fitted to 
nontinrar functions. 
Rerulu. Conxlation coefttetenfs for these functions were 
0.9LO.95 and 0.95 at 1, 2, and 5 min, respectively. At 1 min after 
i~ectian, the relationship of technetium.l)Pm teboroxtme raten. 
tion to blood flow war linear over a wide flow range, becoming 
nonlinear at Aow rates 2.5 ndimin per g. After 5 min the 
retention&w relationship was linear only to 1.5 mUmin per g, 
above which little change in reteentton was noted. Normalined 
myocardial retention, expressed w a percent of Ihe relentian al 
1 m”mt” wr e, was r&o catcutated. At now rates of I, L&3,4 and 
I. 
5 m”,,,h, per g, normalized retention wa IW, 169,228,117 and 
317% at I min and 100. 171,217,139 and 237% at 5 min after 
lnjedion. 
Conelusiom. At I min after injection, the relationship 01 
teohnetium.99m tehoroxime mwcardtial retention to blwd Row is 
well maintained over a wide r&e of Row. Howver, after only 
5 mtn, tracer retention underestimates flow changes at moderate 
rmd high Row rates. Thus, rapid acquisition protocols are nccw 
sary to fully exploit he potential of this proiniring new tracer in 
the rvatuation of myocardlat perfusion. 
,J Am Colt C,,,diol1992:20:?12-9) 
Cardiac imagine with radiotsbeled perfusion tracers contin- 
ues to be thk most important noninvzsive method for the 
evaluation of myocardial pmfusion. In addition to standard 
exercise imaging protocols, coronary flow reserve can now 
he assessed clinically with the use of pharmacologic vasodi- 
lation (l-5). A four- to fivefold increase in myocardial blood 
Row can be achieved with these agents in vascular territories 
with normal coronary arteries (6-8). With this wide range of 
Row now achievable in the clinical setting, it becomes 
critical to define the relationship between a given tracer’s 
retention in tissue and blood Row. This relationship is 
imponant in determinine the accuracv with which myocar- 
dial perfusion can be measured by nuclear imaging tech- 
niques (9). 
Three principal myocardial flow agents are now available 
for clinical use: thallium-ZOt. technetium-99m sestamibi and 
technetium-99m teboroxime. Thallium-201 is the most 
widely used. Its kinetics have been extensively studied 
(9-15). and its clinical utility and limitations are known. 
Thallium.201 has a high extraction fraction by the myo- 
cardium in the ranec of 8SW (9-11). However. as flow 
increases. the extra&n and r&tion decrease (9-11.15). 
Because thallium-201 has law photou energy and a tong 
physical half-life that limits its suitability as an imaging 
agent. other Row tracers have recently been developed. 
Technetium99m sestamihi is one such agent. It has a lower 
extraction than that of thallium-201 (9.14) but a greatly 
prolonged tissue retention (9.14.16.17). As with thallium- 
201, this tracer also demonstrates a reduction in retention 
with increasing flow, thus limiting its ability to accurately 
reflect perfusion at high flow rates (9). 
lcchnetium-?9m teboroxime (Cardiotec) represents the 
most recent Row tracer to be proposed for clinical use 
(18.19). It is a neutral lipophilic boronic acid adduct of 
technetium dioxime (BAT01 compound that demonstrates a 
high level of myocardial tissue extraction (I5,20,21) with a 
first pass retention fraction of about 90% (21). After initial 
“ptake. the rCtiYity clears rapidly Emm the myocnrdium 
(18.20-25) at a rate proportional to blood How (21.25) 
However, there are limited data on the relmionshir, between 
tissue relention of lechnerium-99m teburoxime and myocar- 
dial blood flow. Given the tracer‘s table first oar relent~on 
fraction over a wide Row range (21). a linear correlation 
between retention and Row would be expected. However. 
with rapid differential tissue cleararie this re\inonship may 
twt he maintained. A more complct,: understanding of rhese 
temporal changes in technerium-99a! ceboronime re’cntion it 
required to fully exploit its potential 8% a myocardial perfu- 
sion tracer. 
Thus. ihis study was designed to define the temporal 
changes in the relationship between the myocardial retention 
of technetium-99” tehoroxime and myocwdkrlial blood Row 
measured by micraspheres during the 1st 5 min after tracer 
injection. Tissue retention measured by in vitro cowling 
was determined at different imes after injection over a wide 
flow range in open chest dogs. 
Methods 
The study protocol was approved by the Ccmmiiiee for 
Animal Research at the University of Michigan and per- 
formed in accordance with the “Position of the American 
Heart Association on t&search Animal Use.” adopted Nn- 
vember I I, 1984 by the American Heart Association. 
Exoerimental rzemwPcion. Eleven monarel doer weieh- 
ing 26 to 25 kg we;; anesthetized with in&n& sadi& 
wntoharbital (30 mdka hodv weight). All doas were intu- 
bated and ventilated with bxyge&nriched room air. A 
peripheral venous line and central venous line were inserted 
for intravenous access. Both femoral arteries were catheter- 
ized for continuous aortic pressure monitoring and for xte- 
rial sampling. The electrocardiogram (ECGl was also moni- 
tored continuously. A left thoracotomy was performed and 
the heart carefully suspended in a pericardial cradle. A left 
atrial catheter was inserted through the left atrial appendage 
for microsphere and isotope injection. The position of this 
catheter in the left atrium was confirmed by a left atrial 
pressure tracing. The proximal left circumflex coronary 
artmy was isolated. A Doppler Row pmhe was gently placed 
around it to measure relative coronary Row velocity in order 
to continuously monitor Row conditions during the experi- 
ment. To produce regional flow differences, the left anterior 
de*cen‘linp coronary artery W1L ;wAnted sL”d a snare placed 
loosely around it for subsequent occlusion. 
Tracer prepaticm. The preparation of technetium%m 
teboronlme by our latnnalory has been previously described 
(!I). BrteRy. kits conlainiag vials of teboroxime in a lyoph. 
i&red form were supplied by Sqmbb Diagnostics. Sodium 
perteehnetate technetium-99” was obtained from molybde- 
num-YStechnetium-59” generator? thm had been clutcd 
within 24 h of radiopharmaceutical preparation. All eluates 
were used wilhin 6 h. and mdionuclide purity. aluminum ion 
coment and pH were determmed before us;. Each vial was 
reconstirmed with 1 ml of sodium pertechnetate t chnetium- 
99m containing 5 to lo mCi of radioactivity. After reeonsti- 
tution. each vial vms heated for IS min at IOVC in B b&line 
water i ath. The prepared mdiophammcemical was cwled 10 
room temperature. and the radiochemical purity of the 
product W~F determined with the use of 1.3 x 1 I-cm What- 
man 3 I Et chmmatogmphy strips developed in normal saline 
(0.5%) or normal saline/acetone (5050) solution. The &we!- 
aped chromatogmms were air dried and counted. The per- 
cent of free technetium-99m. reduced/hydrolyzed techne- 
tium-99” and technetium-%n teboroxime was determined. 
Chromatogmphic results indicated that the sum of free 
technetium-99” and reduced/hydrolyzed lechnetium.Wm 
WBE routinely <IO%, whereas the mean mdioehemieal purity 
was 94.5% + 2.3%. 
Experimental prntoml (Fig. Il. Once blood pressure. 
heart rate and relative left circumt?ex eonmary anmy blwi 
Row were stabilized, 0.2 to 0.56 mgjkg of dipyridamole was 
administered intravenously over 4 min. At the end of the 
dipyridamole infusion the left anterior descending coronary 
anery was occluded by the snare. Owe Row and hemody- 
namics were stable (a least 5 min after occlusion). mdiola- 
beled microspheres and SO0 Ci of technetium-99m tebomx- 
ime were injected into the left atrium. Arterial bleed was 
then collected for the definition of arterial input function 
with the use of a Harvard pump for I min lgmup I, n = five 
dogs). 2 min @oup II, n = four dogs) or 5 min (group III, 
n = IWO dogs) after tracer injection. For animals in groups II 
and Ill. scadium.46~labeled micmspheres (half-lie 83.8 
days) (DuPont-NEN, size 15.0 f 0.5 mm) were injected 
simultaneously with the tracer. In group I, microspheres 
were injected 1 min before the injection of technetium-99” 
tehoroxime. This procedure ensured that all dogs had a 
minimum 2.min arterial collection for the measurement of 
Thus. the percent maximal retention is a reliltive value, 
which is independent of the blood collection time. 
Statistical analysis. Blood pressure, heart rate and rela- 
tive coronary blood flow at baseline, after dipyridamole and 
before and after injection of the tracer atid microspheres 
were compared by analysis of variance (ANOVA) and 
expressed as mean value + SEW. For each dog the absolute 
myocardial retention of technetiumd9m teboroxima for each 
segment was plotted against the microsphere-determined 
blood Row. Each retention versus blood Row curve was 
fitted to a nonlinear function. Then, for each group the 
myocardial retention of all segments in a given group was 
plotted against blood Aow and also fitted to a nonlinear 
function. The standard error of the coefficients and the y 
intercept for the nonlinear function in each group were 
determined. 
As an alternate means of assessing the retenlion-flow 
relation, the percent maximal retention for technetium-99m 
tehoroxime was plotted against the myocardial blood Row 
determined by the microspheres in each dog. 
microsphere blood activity (see under “luirasurcme~t of 
myocardtal blood flow”). 
At the end of blood collection. the dogs were killed with 
a saturated solution of potassium chlorideand the heart was 
raddly excised. The left ventricle was cut along the short 
a& into slices approxiniately I cm thick. Each left venlric- 
ular slice wa, lhcn sectioned to yield samples of approxi- 
mately I g. and each aample of myocardium war individually 
weighed. The activity in myocardial and blood samples was 
counted in a well counter (model 5780 Packard). Energy 
windows were defined for technetium-99m (II6 to 160 keVl 
and scandium-46 (840.1,040 keV). Blood acd lissuc samples 
were counted again after 72 h (I2 half-lives of techncrium- 
99m) to correct for scandium spillover into the tcchnetium- 
!X9m window. 
Measurement of myocardial blood flow. Myocardial blood 
Row (MBF, mlimin per g) was delermined by using the 
microsphere technique (26): 
MBF = !C, x F.)IC, 
where C, is the activity in myacarc’um (countslmin per g). 
F, is the rate of the withdrawal pump (mlimin) and C, is the 
activity in collected blood (countsiminl. 
Measurement of twbnetiww99m teberoxime retention. 
Absolute retcrdion (R) (arbitrary units, g-‘I of technetium- 
99m tebomxime was calculated as follows: 
R = C,/C, , 
where Cbi is the blood activity corrected for di!Terent with- 
drawal rates. 
Measurement of percent maximal technetium-!l!lm teborox- 
irne retention. This measurement of retention with the arte- 
rial input function as denominator assuntes that technetium- 
99m teboroxime remains relatively unaltered while it 
circulates in the blood pool. Because of the very rapid 
clearance of technetium-99m teboroxime from the blood 
wol (20.21) t<4% of iniected dose oresent in the blood at 
i min after.iijeclion [2&, very little remains available fo; 
uptake beyond I min after injection. Thus, the correction for 
the arterial input function dppearn valid. Alterations that 
might reduce the availability of technetium.CNm tcboroxime 
for myocardial uptake would have to be very marked and 
occur very early aRer injection. Even with iuch changes, 
there would be little alteration in the blood ~001 activitv after 
1 min. Nonetheless, to rule out this possibility as an &.pla- 
nation for any results observed. we also measured the 
percent maximal retention in each dog, % ::ich is equivalent 
to measuring the percent maximal activity. This measure- 
ment also allowed comparison among the groups. because it 
was independent of each group’s different blood collection 
times. The percent maximal retention (%R,,,) of the tracer 
was calculated fur each individual heart in the following 
nlanner: 
%R,,, = (R x 100)/R,,. 
Results 
Hemodynamte recordings. At baseline before the di- 
pyridamole infusion, the mean systolic blood pressure and 
heart rate were 128 + 6 mm Hg and I50 ? 7 beatslmin, 
respectively. Systolic blood pressure decreased to 108 ? 
7 mm He. (p < 0.0s) after diwridamole. whereas the mean 
heart ra& &as I46 ‘I 6 beat&n (p = NS). At the time of 
tracer injection (at least 5 min after left anterior descending 
coronary artery occlusion), systolic blood pressure wes 
102 + 6 mm Hg and the heart rate was 138 t 8 beats/min. 
After the injection of tracer and microspheres, both blood 
pressure and heart rate remained stable. With dipyridamolc, 
the relative blood flow in the circumflex artery, as measured 
by Doppler ultrasound, increased significantly over the 
baseline value. After tracer and microsphere injection, the 
measured circumflex artery blood Row did not change sig- 
nificantly. 
Microsphere-determitted blood Bow. The myocardial 
blood flow determined by microspheres ranged from 0.01 to 
II.71 mllmin per g in group I. 0.01 to 7.48 mllmin per g in 
group II and 0.02 to 4.88 mllmin per 8 in group Ill. 
Myocardial retention of technetium-99m teboroxime. 
There were 424 ventricular segments in group I, 308 in group 
II and 166 in group HI. Table I shows the nonlinear fit 
equations and correlation coefficients for all experiments in 
the three groups. The equations of the curves fitted to the 
overall data for each group are also shown (p a 0.001 for 
each group). Figure 2 shows an individual example from 
each group of the relationship between technetium-99m 
teboroxime retention and microsphere-determined blood 
flow. There is a progressive decline in slope and loss of 
linearity with time. 
Percent mxilnal ntywadial retention of technetium-YYm 
teboroxime. The graphs in Figure 2B depict the r&&c 
retention cxprcsscd as a percent of the ma:ximum for each 
erample compared with microsphere-determired blood 
Row. One minute after tracer injecdon. the increase in 
relative retention was linear in relation to blood flow over a 
wide Row range. Above a Row rate of 4.5 mlirnin per g the 
increase was more gradual. In contrast. at 5 min after tracer 
injection. the data indicate a linear relation only up to a flow 
rate of 2.5 mllmin per g. Above this Row rate. little change in 
relative tracer retention was noted. 
Normalized retention of teehnelium.99m iehoroxime. As a 
further means of comparison. a nonnalincd tissue relention 
was also determined (Fig. 31. Myocardial retention valw 
were calculated at Row rates of 1,2.3,4 and 5 mllmin per g 
based on the fitted equations for individual data in each 
group. These calculated retention values were then cx- 
pressed as a percent of the retention determined at a Row 
rate of I mllmin per g. The standard error of the fitted 
equation for each group was used to determine the error of 
the normalized retention v&es. P.: with the percent maxi- 
mal retention, the normalized retention measurement is 
indeocndent of blood inout function. 
jhc normalized retehtion values determined at the five 
flow rates were 100 i 7%. 169 t 11%. 228 ? 15%. 277 f 
20% and 317 ? 25% at I mitt after injection, and 100 -r 12%. 
171 ? 20%. 217 ? 30%. 239 ? 43% and 237 ? 56% at 5 min 
after injection. At I min after injection the relative incre- 
ments in retention between flow rates nf I to 2.2 to 3.3 lo 4 
and 4 to 5 ml/min ocr e were 69%. 59%. 4% and 40%. 
respectively. At 5 iin tie corresponding valueb were 71%. 
46%. 22% and -2%. respectwely. The change in the incre- 
ments of retention at 5 min showed a dramatic progressive 
reduction. In cnmgwison. at I min this change was much 
more gradual. 
Assessment of myoeardisl clearattee from the teehnetium- 
!?hn tebomxime rete~~tion data. The determination of rctcn- 
eon data at three different imes allowed a hmited evaluation 
of technetium-Y?Im teboroxime myocardial cteamnce. Figure 
4 shows the retention dam at Row rates of 1. 2. 3 and 
4 mVmin per g derived from the fitted curve of each group 
versus the three !inte prints. This graph demonstrates the 
differentral clearance phenomena. Al high Row rates 
14 ml:min per@ tracer reiention decreases drkatically from 
0.218 r 0.016 to 0.066 i 0.012 pm’ between the I- and S-min 
mark after injection. At lower A&v rates (1 mumin per@ this 
reduction in retained technetium-Y9m tcboroxime is more 
gradual. decreasing from 0.079 + O.fC6 to O.@2g + 0.003 g- ’ 
between I and 5 min after injection. 
Discussion 
lnilial tissue relentian of tcchnetitun-YYm tebwoxime am! 
myocardisl blood Row. The principal findings of this study 
arc that initial technetium-YYm teboroxime tissue retention 
has a wrii maintained rclatioaship to myocardial blood Row 
over a clinically relevant flow range IO lo 4.5 mllmin per g). 
However, after 5 mitt the dynamic range of technetium-!Bm 
tebcroxime retention is markedly r:duced relative tc Row. 
The clinical implication ofthis ot&atron is a potential oss 
of sensitivity in determining regional differences in coronary 
Row rcscrvc. On the other hand. if retention can he mea- 
sued early after injection. myocardial blood flow ca:~ be 
determined with a high degree of accuracy. Such early 
measureme”, may be clinically achicvahle wilh the use of 
rapid data acquisilio” by mukiheaded slngk-phoron dmis- 
sio” computed tomographic (SPECT) systems. Indeed. lech- 
iwith retention at I ml/mm peig awgncd a value of 100% in each 
group,. Ewor bars rep~sen, Ihe standard error of ,hc cquadon~ for 
each group al the respective Row raler (see Table I). Technclism- 
99m lehororime showed a reasonable increme”, in rtxentio” for 
inxeasing flow r&s early afkr injection f/ and 2 mink Huwever. a, 
5 mi” d~ese incrcmcnla decreased progrerwely I” reladonship Lo 
the i”creaxe in Row. 4 I mi”: fS * mi”: 0 5 min. 
Figure 2. A, Examples of techne- 
dum-9% ,cbororime allao,ute re. 
tention versus microrphcrc-deler- 
alii.cd myocardidl blood dew at 
I mi” (Do8 20385,. 2 mi” (dog 
KM,, and 5 mi” ,““g 185271 after 
mjeclio” with 95% confidence inter- 
vals ,equadons and correladan CO- 
sfficients for each example are 
noted in Table IL Note the progres- 
sive loss of slope and linearity with 
time. 8, Percent maximal retenlio” 
versus microrphere-determined 
myacardial blcmd Bow for the same 
examples as in A. At I mi” rhc 
relalive re,e”tio” increased linearly 
I” relation 10 blood Bow up toa Row 
014.5 m,,m,“per8and,henbeeame 
more gradual. A, 5 ml” Ihe relalion- 
ship WE linear up ,o a Row rale of 
2.5 mllmi” per 8. Above this Row 
rale there was lhlle change in rela- 
tiw rete”“o”. with values between 
80% to IWJ% of the maximum. 
“etiom-99m reboroxime is a promising tracer with the poten- 
lial for no”i”vasiw evaluation of myocardial perfusion over 
a wide range of blood Row. 
Validity of this model. This model combined the use of a 
pharmacologic vasodilator and a coronary artery occlusion 
Lo produce heferogencous Row mfes throughout the myocar- 
dium. Blood Row ranged from very low in the occluded 
,erri,ory to very high in the normal region. The border zcme 
around the occluded territory lhad mild ,o moderate in- 
creases in flow between lhe two extremes. Maximal induced 
Figure 4. Tebomxime retendo” a, Aows of I, 2. 3 and 4 mlimi” per 
8 derived from Lhe retention-myocardial blood Row relalionships 
versus “me afterinjeclio”. Nale the rapid decrease in refcntio” over 
lime a, high Row mles. At lower Row rates this change was m”re 
gradual. 0 I mlimin pcrg; *2 mUmi” perg: U-3 mlimi” per*; 
I- 4 mllmin per *. 
Row rates were varied among dogs by using different doses be ah;fost linearly related to Row. Indeed. the present study 
of the vasodilator. This technique was successful. judging by support> this hypothesis. although the re!ation between 
the wide range of microcphex !!etermioed Row rates iii. tracer retenttoo and Row changed aver the tst 5 min after 
duced. The use of in vitro tissue counting of a large number mjectvx. 
of segments in each dog allowed dcrcrmination of the reten- Usmg isolated heart preparations with a multi-indicator 
lion-flow relationship with high staistical power. ddution rechniquc, Leppo et al. (151 showed that the 
Tissue activity was corrected for the integral of the blood peak extract!on. capillary permeability and net extm .on 
activity to calculate absolute tracer retention. Accounttng (= retentton) were all higher for technetium%m teboroxime 
for the arterial input function appears to be appropriate than for thallium-201. They also reported a tendency fcr the 
because myocardial uptake of most perfusion tracers contin- peak extraction to decrease with increasing blood flow. Both 
ues aIter their first pass through the coronar) wculatton. We tracers showed an i verse linear relation between Row and 
did not correct for potential metabolic alterations of t&w- peak extraction fraction and a linear relation between capil- 
tium-99m tebomxime after injection, although such change lary flux and coronary perfusion. confirming our observa- 
could theoretically lead to an overestimation of the true tions. However Leppo et al. (15) demonstrated a ditTosion 
arterial input function. However, a recent study (20) has limitatton at a relatively low t%w rate of 2.5 mlimin per g 
shown that at I min after in&ion only 1% of inicctcd dose lissue in the blood-wfused is&red rabbit heart. In addition 
of technetium-99m teboroxime is bound to red blood cells. to obvious specieshifferences. there are important methcd- 
This observation supports the view rhat these alterations ologic differences between their work and our present study. 
are not of major importance in the first minutes after The multi-indica;or diloiion techniqce derived variables 
injection. In addition. the clearance of technetium-99m te- based on the continuous recovery of activity from the 
boroxime from the blood pool is so rapid (20.21) that the venous effluent of the isolated hean. Comparison of kinetics 
cotneqoeoces of later alterations in the compound are prob- of a vancular tracer (radiolabeled albumin) and technetium- 
ably minimal. In support of our approach. the relative 99m tebomxime allowed the instantaneous characterization 
retention data. which are Independent of blood collection of tmccr extraction. In contrast. our data ax based on tracer 
time, and the absolute retention dam yielded similar conclw tissue retention at various times after injection in the intact 
sions reaardina the technetium-99m tehoroxime retention- animal. However. the tiiewol results of the two studies 
blood R&v r&tionships. suggest here is less diffusion limitation at comparable blood 
The eouations for the fitted carves of individual exoen- flows for technetium-99m teboroximc in our model, which 
meats sh&n in Table 1 were almost identical in grottd 111. may reflect maintained integrity of vascular coupling in an 
However. there ME some variahilitv in the eoua:ions within intact ammal. 
groups I and IL This variability dies not slier the overall 
corrlusions of this study hecuse all individual curves in 
group 1 were also linear over a wide flow range. The 
individual curve differences may be explained in part by the 
uifferent ranges of blood Row between errperiments. Another 
possible explmttlion may be lhal slight ditferences in the 
length ofth Icft atrial catheter and its position within the left 
atrium may have varied the tracer delivery time to the 
myocardium between experiments. This could lead to some 
variability in retention mea~umments early after injectho. 
Techtteliom-99m teboroxime retention: comparison with 
previous studies. Technetium-Wm teboroxime is a neulral 
lipophilic BAT0 compound. The exact mechanism of its 
myocardial retention is not known. Given its neutral lipo- 
philic nature, it most likely follows nonionic pathways (20). 
However, it is not clear whether it enters the cytosol or 
binds exclusivelv to the cell membrane lioid bilavcr. 
Several studies have dentonstratcd high inilii! &oardiat 
extraction (15,20,21) and high capillary permeability surface 
area product (IS). Although we did not specifically measure 
these variables, our data support these previous studies by 
demonstrating that retention accurately reflected blood Row 
over a wide range early after iniection. 
The clearance kinetics of technetium-99m teboroxime 
have been well studied. Rapid myocardial clearance has 
been demonstrated in cell culture models (22), animal mod- 
els 120.21,23,25) and human studies (l&24). The clearance 
rate has been shown to correlate with bled Row (21.25). and 
rapid disappearance ofexercise defects has beenobserved in 
a clinical study as well (19). We did not examine the tracer 
clearance directly in this study; however, we did observe a 
progressive reduction in the slope of the retention-flaw 
relation and a loss of linearity over time. Tracer tissue 
retention decreased more rapidly at higher flow tales (Fig. 
4). an effect consistent with the differential clearance prop 
erty of this tracer. 
Impliitioos for lmagiog ~rotacols. Our results indicate 
that clinical imaeinr: orotocols must incomorate the rapid _ _. 
acquisition of data after technetium-99m teboroxime iojec- 
lion. This is in order to ?) c.zoitaiize on the excellent earlv 
relation of tracer reteotio.; to‘blwd flow, and 2) to prevent 
the potentially reduced sensitivity in detecting Row reserve 
differences by delayed data acquisition. Given the time 
course of routine SPECT imaging, single-headed romo- 
graphic systems may be of limited use with this agent. 
Normal regions with high Row after a given stress will 
Our data a&support previ& work from our laboratory already have had significant clearance of activi:y doting 
(21) that showed a stable Brst-pass retention fraction over a image acquisition aod thus may be difficult to differentiate 
wide range of blood flow and suggested that retention would from regiom distal to a coronary artery stenosis wbcre lhc 
clearance of technetium-99m would be more gradual. In B 
canine model with coronary stenosis, Li et al. (23) showed 
that both Il.min and 5.min SPECT acquiGtions initiated 
early (I min) after technetium@m tebomxime injection led 
10 underestimation of relative microsphere-determined Raw 
deficit? after dipyridamole administration. The investigators 
amxbuted this undercsumation to r&dual activity from a 
preceding injection. However, the results of our study 
suggest that the underestimation observed by Li et al. (23) 
may also have been related in part !o a bss of sensitivity due 
to the differential clearance accompanying a wide flow 
range. 
An additional problem with routine SPECT imaging is the 
acquisition of myocardial tracer activity that is rapidly 
changing over time. Th!s factor could potenlially lead to 
imaee artifacts and thus interfere with data intemretation 
(27&j. The problem is compounded when tracer’distribo- 
don is changing at different rates (23), as would be the case 
when there are regional differences in flow. Becrus? of these 
problems, cliaical studies (l&19) to date have principally 
involved planar acquisition protocols. However, even planar 
imaging involves projections acquired al d&rent limes with 
potentially different tracer distribution. 
On the other hand, the newer multiheaded SPECT sys- 
tems may provide sufficient :emporal resolution to overcome 
the drawbacks of standard imaging techniques with fhis 
tracer. Nakajima et al. (24) used a dynamic triple-headed 
SPECT acquisition with 30 sets of I-mir. projections begin- 
ning at the time of injection in six patients at rest. Excluding 
the 1st min, which had blood pool artifact, good image 
quality was achieved and time-activity data acquired. Ac- 
cording to these investigators (24), the minimal lime for a 
continuous rotation is 10 s with the triple-head& SPECT 
camera they describe. The potential for dynamic datlt acqui- 
sition with such systems may permit the absolute quantili- 
cation of blood flow by applying tracer kinetic models to 
time-activity data. Such a tracer kinetic model for techne- 
tium49m teboronime could utilize both the excellent early 
retention-flow relationship, as well as the relationship of 
clearance rate to blood flow (21,25). 
The present study used dipyridamole to maintain stable 
experirkntal conditions over a prolonged period. Clinically, 
however, it may be advantageous to utilize the rapid 
decrease in myocardial blood flow that occurs after ces- 
sation of either exercise or an adenosine infusion (529). 
Use of a short-acting vasodilator or exercise may prolonp. 
the linear relation of retention to Row by d&y& thk 
clearance in segments with high Row rates, thus permitting 
longer data acquisition times with a more stable tracer 
distribution. 
Conclusions. Techn:dum-9Ym tehoroxime demonstrates 
unique kinetics among available gamma.emittiog myocardial 
how tracers. Our study shows that a delay in awuirina 
!echnetium-%m teboroxime retention data may lead io sig- 
nificam underestimation of regional blood flow differences at 
moderate to high Row rat& This effect may limit the 
diffcrentiaGon of regions with different levels of coronary 
Raw reserve. In contra& early after injection there is a well 
maintained relationship between technetium49m teborox- 
ime tissue retention and myocsrdial blood Row over a 
clinically relevant ROW range. Thus, there appears io be 
promise for this agent in the use of rapid acquisition pmto- 
cols and the development of a kinetic model for the estima- 
tion of regional myocardial blood Row. 
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